BioDelivery Sciences International, Inc.: Business Overview, Financials & Competitive Analysis
BioDelivery Sciences International, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Specialty pharma player with defensible technology platform and chronic-pain franchises, but constrained by scale and competitive positioning in a commoditizing market. BDSI operates in a mature market with established products (Belbuca, Symproic) and proprietary drug-delivery technology providing differentiation. However, the company faces competitive pressures from larger pharma players.
What is BioDelivery Sciences International, Inc.'s industry? BioDelivery Sciences International, Inc. (biodeliverysciences.com) operates in Pharmaceuticals. AskCyborg classifies BioDelivery Sciences International, Inc. under Pharmaceuticals in its company registry.
BioDelivery Sciences International is a specialty pharmaceutical company focused on chronic pain management and related conditions. The company leverages its proprietary BioErodible MucoAdhesive (BEMA) drug-delivery t...
Cyborg Score thesis
Specialty pharma player with defensible technology platform and chronic-pain franchises, but constrained by scale and competitive...
Read the full analyst-debate transcript →Get the Latest BioDelivery Sciences International, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBioDelivery Sciences International, Inc. Overview
Pro stress-test →BioDelivery Sciences International is a specialty pharmaceutical company focused on chronic pain management and related conditions. The company leverages its proprietary BioErodible MucoAdhesive (BEMA) drug-delivery technology platform to develop and commercialize pharmaceutical products, with flagship products including Belbuca (buprenorphine) and Symproic (naldemedine).
Strategic Profile
Pro stress-test →BDSI competes in the specialty pharma space with differentiated drug-delivery technologies rather than first-to-market compounds. The company has secured patent protection for its key asset Belbuca with exclusivity extending to 2032 against generic competition. The company remains focused on expanding its portfolio and improving patient access to chronic pain treatments across various therapeutic modalities.
Competitive Landscape
Pro stress-test →BDSI competes against major pharma companies and specialized pain-management competitors including Collegium Pharmaceutical (opioid products), Purdue Pharma legacy competitors, and generic manufacturers. Differentiation relies on BEMA technology and established commercial relationships rather than blockbuster drug development. Larger competitors with broader portfolios and manufacturing scale create pricing and market-access pressures.
Industry Context
BioDelivery Sciences International, Inc. operates in Pharmaceuticals.
Key facts
Founded: 1997 · Headquarters: Raleigh, North Carolina, US · Employees: ~200 (as of 2021) · Revenue: N/A · Market cap: ~$577M (as of March 2022)